Skip to main content
Caplight Logo









LinqMed Inc.

LinqMed Inc.

Private
Chiba, TokyoHealthcare & Life Scienceshttps://linqmed.co.jp/

Last Round

Series B

Extension

May 12, 2025

Total Funding Raised

$39.55M

Company Overview

LinqMed Inc. is a radiopharmaceutical company developing a drug discovery platform and innovative 'visible' anti-cancer treatments using the copper radioisotope 64Cu.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Imaging, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Data as a Service

AI Layer

Non-AI

Keywords

radiopharmaceuticalstheranosticsradiopharmacancer therapycopper-6464Cu-ATSMtargeted radionuclide therapyradioligand therapyPET imagingoncologyclinical stage biotechradioisotope productionhypoxic tumor targetingdrug discovery platformglioblastoma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LinqMed Inc. Comparables

Compare LinqMed Inc. with similar companies based on industry and business-model similarity.

LinqMed Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alpha Fusion Inc.
81%
NUCLIDIUM AG
80%
RadioMedix, Inc.
77%

LinqMed Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 12, 2025
Series B ExtensionApr 9, 2025
Series BJan 10, 2025
Series ADec 22, 2023
GrantDec 22, 2023

LinqMed Inc. Investors

Notable investors and investment history

LinqMed Inc. investors
InvestorRounds
Sumitomo Mitsui Trust BankSeries B Extension
Keio Innovation InitiativeSeries B Extension
Mizuho CapitalSeries A
New Energy and Industrial Technology Development OrganizationGrant
Chibagin CapitalSeries B Extension
Bio-Sight CapitalSeries A, Series B Extension
Nissay CapitalSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2025

    $2M round with Nissay Capital participating.

  • Apr 9, 2025

    $14.47M round with Sumitomo Mitsui Trust Bank and Chibagin Capital.

LinqMed Inc. Filings

Explore SEC and related filing metadata, where available.

LinqMed Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about LinqMed Inc.'s valuation, stock price, and market status.

Is LinqMed Inc. a public or private company?

LinqMed Inc. is a private company.

What is the current stock price of LinqMed Inc.?

LinqMed Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is LinqMed Inc. worth (valuation)?

Valuation information for LinqMed Inc. is not publicly available.

Can I buy LinqMed Inc. stock?

LinqMed Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was LinqMed Inc.'s last funding round?

LinqMed Inc.'s most recent funding round was Series B Extension on May 12, 2025.

Who are the main investors in LinqMed Inc.?

Key investors in LinqMed Inc. include JIC Venture Growth Investments, DBJ Capital.

Will LinqMed Inc. IPO soon?

No public IPO plans have been announced for LinqMed Inc..

How can I track LinqMed Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LinqMed Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersChiba, Tokyo
Year Founded2022
Last FundingMay 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?